

1 *This document is the submitted manuscript version of a published article*
2 *that appeared in its final form in the International Journal of Pharmaceutics, copyright ELSEVIER.*
3 *To access the final edited and published work see: <https://doi.org/10.1016/j.ijpharm.2021.120464>*

4 **Microfluidics for nanomedicines manufacturing: an affordable** 5 **and low-cost 3D printing approach**

6
7 Mattia Tiboni¹, Massimiliano Tiboni², Alessio Pierro³, Marco del Papa³, Simone Sparaventi³, Marco Cespi⁴ and Luca
8 Casettari^{1*}

9
10 ¹*Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino*
11 *(PU), Italy.*

12 ²*R&D department, Idrofoglia s.r.l., Via Provinciale, 14, 61026 Lunano (PU), Italy*

13 ³*R&D department, TechFem s.p.a., Via G. Toniolo, 1/d, 61032 Fano (PU), Italy*

14 ⁴*School of Pharmacy, University of Camerino, 62032 Camerino (MC), Italy*

15 16 **ABSTRACT**

17 During the last decade, an innovative lab on a chip technology known as microfluidics became
18 popular in the pharmaceutical field to produce nanomedicines in a scalable way. Nevertheless, the
19 predominant barriers for new microfluidics users are access to expensive equipment and device
20 fabrication expertise.

21 3D printing technology promises to be an enabling new field that helps to overcome these drawbacks
22 expanding the realm of microfluidics. Among 3D printing techniques, fused deposition modeling
23 allows the production of devices with relatively inexpensive materials and printers.

24 In this work, we developed two different microfluidic chips designed to obtain a passive micromixing
25 by a “zigzag” bas-relief and by the presence of “split and recombine” channels. Computational fluid
26 dynamic studies improved the evaluation of the mixing potential. A fused deposition modeling 3D
27 printer was used to print the developed devices with polypropylene as manufacturing material. Then,
28 two different model nanocarriers (*i.e.*, polymeric nanoparticles and liposomes), loading cannabidiol
29 as model drug, were formulated evaluating the influence of manufacturing parameters on the final
30 nanocarrier characteristics with a design of experiments approach (2-level full factorial design).

31 Both the chips showed an effective production of nanocarriers with controllable characteristics and
32 with a good loading degree.

33 These polypropylene-based microfluidic chips could represent an affordable and low-cost alternative
34 to common microfluidic devices for the effective manufacturing of nanomedicines (both polymer-
35 and lipid-based) after appropriate tuning of manufacturing parameters.

36

37 **Keywords:** FDM; nanomedicine; polymeric NPs; liposomes; cannabidiol; drug delivery systems,

38 CFD.

39

40 **1. INTRODUCTION**

41 The scale up of nanocarriers manufacturing is one of the main issues for the translation from the
42 bench to the clinic of innovative drug delivery nanosystems (DDS) (Metselaar and Lammers, 2020).
43 Common methods such as thin layer evaporation or nanoprecipitation involve several steps and
44 usually lack of reproducibility, controllability, and low production rate (Valencia et al., 2012). In a
45 typical colloidal system production, the procedure is based on a bottom-up approach, where most of
46 the theoretical works describing the formation process are based on the classical nucleation theory
47 (Liu et al., 2019; Mer, 1952).

48 During the last few years, the concept of “lab on a chip” became popular among researchers
49 facilitating the development of more precise systems for healthcare applications by the
50 miniaturization of conventional processes (Daw and Finkelstein, 2006; Wu et al., 2020). Among
51 different lab on a chip technologies, microfluidics became an innovative manufacturing approach in
52 the pharmaceutical and biomedical fields by manipulating nanoliters scale of fluids in submillimeter
53 channels. It allows to effectively control the final formulation characteristics by tuning the
54 manufacturing parameters (Martins et al., 2018).

55 Even if the microfluidic method is not a new story, the colloidal DDS-assisted production has drawn
56 increased interest due to several advantages such as high reproducibility, low batch-to-batch
57 variation, better control over particle characteristics, and ease to scale-up (Zhao et al., 2020).
58 Moreover, microfluidics can sharply increase the surface area-to-volume ratio by several orders of
59 magnitude allowing a more efficient mass and heat transfer within the system (Capretto et al., 2011).
60 The production of nanocarriers within this technique needs mixing of fluids in sub-millimeter
61 channels that become difficult into simple smooth microchannels where the flow remains laminar.
62 To overcome this problem different micromixers have been developed and classified as active and
63 passive micromixers (Hessel et al., 2005). Active micromixers take advantage of external sources of
64 energy such as electric or magnetic fields and acoustic waves. Even if the mixing is rapid within these
65 devices, they are more difficult to fabricate, integrate, and operate compared to passive micromixers.
66 Passive micromixers are based on shape modification of the structure of microchannels to produce a
67 specific flow pattern that enhances mixing such as the presence of obstacle, bas-reliefs, or split and
68 recombine microchannels that induce whirl flow and recirculation creating transversal mass transport
69 (Lee et al., 2016).

70 Common microfluidic device fabrication protocols include photolithography and micromachining.
71 The predominant barriers for new users and alternative applications are access to expensive
72 equipment and device fabrication expertise.

73 3D printing technology promises to be an enabling new field that reduces complexity and costs and
74 thus expands the realm of microfluidics (Pranzo et al., 2018). Among the 3D printing techniques
75 currently available, fused deposition modeling (FDM) utilizes a heated nozzle to extrude a
76 thermoplastic polymeric filament layer over layer to form the desired 3D object (Melocchi et al.,
77 2020). This approach presents several advantages including relatively inexpensive materials and
78 printers, low maintenance costs, a large selection of commercially available materials, the ease of
79 initial use and the ability to start, stop, and integrate complexity on the fly (Romanov et al., 2018).

80 Compared to expensive microfluidic chip production techniques, 3D printing enables a reduction in
81 the resources and skills required to manufacture microfluidic devices, micromixer included as already
82 reported in the literature (Morgan et al., 2016; Tothill et al., 2017; Vasilescu et al., 2020; Waheed et
83 al., 2016).

84 In this work, we developed two different 3D printed microfluidic chips using polypropylene (PP) in
85 an FDM 3D printer. The two chips rely on passive micromixing due to the presence of a “zigzag bas-
86 relief” and a “split and recombine” channel shape, respectively. PP was selected as the manufacturing
87 material because it is a robust, flexible, and chemically inert polymer, resistant to the majority of
88 organic solvents such as acetone, acetonitrile, ethanol, and methanol. (Price et al., 2020).

89 The microfluidic designs were first characterized by computational fluid dynamics (CFD) studies and
90 then printed to be evaluated for the manufacturing of nanocarriers.

91 Both lipid-based and polymer-based nanocarriers were produced and characterized, encapsulating
92 cannabidiol (CBD) as a model active molecule since it has shown different therapeutic effects such
93 as anti-inflammatory, pain-relieving, antioxidant, immunomodulatory, antidepressant, antiepileptic,
94 anticonvulsant and, antineoplastic effects (Pagano et al., 2020). The influence of manufacturing
95 parameters was evaluated with a design of experiment (DoE) approach.

96

97 **2. MATERIALS AND METHODS**

98 **2.1 Materials**

99 Neutral polypropylene 3D printing filament was kindly gifted from Verbatim (Italy), Phospholipon
100 90-G (SPC, soybean lecithin, 94 % of phosphatidylcholine) was kindly provided by Lipoid
101 (Germany), cholesterol was kindly provided by Croda (United Kingdom), poly(lactic-co-glycolic
102 acid) (PLGA Purasorb[®] 5002A) was kindly provided by Corbion (The Netherlands). Cannabidiol
103 (CBD) was purchased from VerusHemp (United Kingdom). All the other solvents used were HPLC
104 grade.

105

106 **2.2 Design of microfluidic chips**

107 The original 3D projects were designed using the computer aided design (CAD) software SolidWorks
108 2018 (Dassault Systèmes, France). The two designs were developed to have an effective passive
109 micromixing with “zigzag” bas-relief and “split and recombine” channels. The files were exported
110 from the CAD software as STL (Stereolithography interface format) to be then converted in machine
111 language with a computer aided manufacturing (CAM) software (STL file provided as supplementary
112 material).

113

114 **2.3 Computational fluid dynamics studies**

115 The single-field incompressible Navier–Stokes equations modeled with the volume-of-fluid (VOF)
116 method was used for the CFD simulations of two-phase flow (Hirt and Nichols, 1981). The VOF
117 model is a surface-tracking technique that uses a fixed mesh system to solve geometry interfaces and
118 interactions between different fluids. The fluid dynamics of two-phase flows are described with a set
119 of single-field equations which are obtained through conditional volume averaging of the local
120 instantaneous conservation equations of mass and momentum.

121 The indicator function (α) allows obtaining the location of the interface, which is equal to the volume
122 fraction of a phase in each cell. The solution of the continuity equation (1) for the volume fraction
123 (α) of one of the phases enables to track the evolution of the interphase surface (Hirt and Nichols,
124 1981).

125

$$126 \quad \frac{\partial \alpha}{\partial t} + \nabla \cdot (\alpha U) = 0 \quad (1)$$

127

128 where α is the volume fraction and U is the velocity field. Since α is discontinuous at the phase
129 boundaries, and it is important to have this discontinuity sharp enough to precisely capture the
130 interface between two phases, an additional term has been introduced, which is a function of the
131 relative velocity between two phases U_r , as in equation (2).

132

$$133 \quad \frac{\partial \alpha}{\partial t} + \nabla \cdot (\alpha U) + \nabla \cdot (\alpha(1 - \alpha)U_r) = 0 \quad (2)$$

134

135 It is worth noticing that the equation is exact because no assumptions are employed in its derivation.
136 In the VOF method, only the single continuity and momentum equations are solved for the entire
137 domain. This approach is known as the “one-fluid” approach (Gueyffier et al., 1999). Therefore, the
138 variables and material properties are defined as volume averaged of the two phases in each cell, as
139 shown in equations (3) and (4)

140

$$\rho = \alpha\rho_1 + (1 - \alpha)\rho_2 \quad (3)$$

$$\mu = \alpha\mu_1 + (1 - \alpha)\mu_2 \quad (4)$$

143

144 The governing equations were solved with the finite-volume-based, open-source CFD toolbox,
145 OpenFOAM (OpenCFD Ltd) (Desir et al., 2020; Weller et al., 1998). The dispersed phase, water,
146 flows into the micromixer from one inlet, while the continuous organic phase, e.g., Acetonitrile and
147 ethanol, flows into the chip from the other inlet and mixes with the water. At the inlet, a zero-pressure
148 gradient and constant velocity were used as boundary conditions. At the outlet, the velocity and
149 volume fraction were set to be zero-gradient, and the pressure to be atmospheric.

150

151 **2.4 3D printing of polypropylene microfluidic chips**

152 3D-printed PP microfluidic chips were produced via fused deposition modeling (FDM) using an
153 Ultimaker 3 printer (Ultimaker, The Netherlands). Both the developed devices were printed at a print
154 speed of 25 mm/s with a nozzle temperature of 205 °C. The infill density was set at 100 % and the
155 build plate was preheated at 85 °C after the application of a polypropylene adhesion sheet (Ultimaker,
156 The Netherlands). The original STL file was converted to a print pattern using Ultimaker Cura 4.6.1
157 software (Ultimaker, The Netherlands). Alternating 50 µm thick layers were printed such that the
158 pattern ran parallel to the length of the device, enabling leak-free and semi-transparent devices to be
159 printed with PP. Probe needles were used to connect the chip with pump tubing. The effective
160 dimensions of the microfluidic channels were evaluated using a digital microscope and then, a colored
161 aqueous solution was run through the microchannels to confirm that the fluids were free to flow
162 through the chips.

163

164 **2.5 Microfluidic formulation of polymeric nanoparticles**

165 For the preparation of PLGA NPs by microfluidics, the 3D printed chip was connected to two
166 syringes mounted on two syringe pumps (Aladdin syringe pump, WPI Europe, Germany) through
167 polyethylene tubing. A precise amount of PLGA alone or PLGA and CBD dissolved in acetonitrile
168 was pumped against water at controlled flow rates and the samples were collected from the outlet
169 of the chip. Two different final polymer concentrations were evaluated, *i.e.*, 5 and 10 mg/mL.
170 The flow rate ratios (FRR) evaluated were 1:3 and 1:1 (ACN:water) and the total flow rates (TFR)
171 were 10 and 12 mL/min. The amount of CBD added was 3 % w/w (Loading degree max 3%). The
172 organic solvent was evaporated under a stream of nitrogen (Trotta et al., 2002). The specific

173 experimental conditions used for the preparation of all NPs were defined according to the DoE
174 reported in the method section 2.7.

175

176 **2.6 Microfluidic formulation of liposomes**

177 For the preparation of liposomes by microfluidics, the 3D printed chip was connected to two
178 syringes mounted on syringe pumps (Aladdin syringe pump, WPI Europe, Germany) through
179 polyethylene tubing. A precise amount of SPC and cholesterol (3:1 w/w) or SPC, cholesterol, and
180 CBD dissolved in ethanol was pumped against water at controlled flow rates, and the samples were
181 collected from the outlet of the chip. Two different final lipids concentrations were evaluated, *i.e.*, 10
182 and 15 mg/mL. The FRR evaluated were 1:3 and 1:5 (ethanol:water) and the TFR were 10 and 12
183 mL/min. The amount of CBD added was 3 % w/w (Loading degree max 3%). The organic solvent
184 was evaporated under a stream of nitrogen (Trotta et al., 2002). The specific experimental conditions
185 used for the preparation of all liposomes were defined according to the DoE reported in the method
186 section 2.7.

187

188 **2.7 Design of the experiments (DoE)**

189 The effect of chip design and the preparation conditions (polymer/lipids concentration, FRR, and
190 TFR) on NPs/liposomes size and polydispersity were evaluated by applying 2 levels full factorial
191 design, characterized by 2^f experiments (where 2 is the number of levels and f is the number of factors)
192 as reported in table 1.

193

194 **Table 1.** Two levels full factorial design matrix for the evaluation of the effect of chip design and preparation
195 conditions.

RUN	CHIP	CONCENTRATION	TFR	FRR
1	Z	-1	-1	-1
2	C	-1	-1	-1
3	Z	+1	-1	-1
4	C	+1	-1	-1
5	Z	-1	+1	-1
6	C	-1	+1	-1
7	Z	+1	+1	-1
8	C	+1	+1	-1
9	Z	-1	-1	+1
10	C	-1	-1	+1

11	Z	+1	-1	+1
12	C	+1	-1	+1
13	Z	-1	+1	+1
14	C	-1	+1	+1
15	Z	+1	+1	+1
16	C	+1	+1	+1

196

197 The design is characterized by a categorical factor, the chip design coded as Z (zigzag bas-relief) or
 198 C (split and recombine channels), and by three numerical factors, concentration, TFR, and FRR coded
 199 as -1 and +1. The numerical values of the coded variables are reported in table 2. The two nanocarriers
 200 were prepared by varying all the parameters within the same range with the only exception for the
 201 FRR. In this case, a larger range was selected since for values higher than 1:3 the preparation of the
 202 polymeric nanoparticles was not possible due to the precipitation of the polymer and chip clogging.

203

204 **Table 2.** Manufacturing condition and their corresponding numerical values of the coded variable.

Coded Variable	NPs			Liposomes		
	Concentration	TFR	FRR*	Concentration	TFR	FRR*
-1	5 mg/ml	10 ml/min	0.33	5 mg/ml	10 ml/min	0.2
+1	10 mg/ml	12 ml/min	1	10 mg/ml	12 ml/min	0.33

* The FRR values used in the DoE represents the volumetric ratio of the organic and aqueous phases mixed through the microfluidic chip. Thus, the values of 0.2, 0.33, and 1 were used to numerically describe the FRR 1:5, 1:3, and 1:1 respectively.

205

206 All the NPs and liposomes prepared according to the DoE were characterized in terms of average
 207 particle size and polydispersity index as described in section 2.8. These two parameters represent the
 208 responses of the designs.

209 For each response, the two design were analysed by multilinear regression using a first order model:

$$y = \beta_0 + \sum_{i=1}^n \beta_i \cdot x_i + \sum_{i<j}^n \beta_{ij} \cdot x_i x_j$$

211

212 Where y is the response, β_0 is the model constant, β_i is the coefficient corresponding to the variables
 213 x_i (linear terms), and β_{ij} are the coefficients associated with the variables $x_i x_j$ (first-order interaction
 214 terms).

215 The goodness of fitting was evaluated through the adjusted coefficient of multiple determination
 216 (R^2_{adj}), while the residues analysis was used to test if the models meet the assumptions of the analysis.
 217 The ANOVA and coefficient analysis were instead used to identify the relative magnitude and the
 218 statistical significance of all the model terms.

219 The DoE design and analysis was carried out with the Minitab 18 statistical software (2017 Minitab,
220 Inc.).

221

222 **2.8 Nanocarriers physicochemical characterization: DLS, AFM, DSC, LD%**

223 Prepared formulations were characterized for their average particle size (Z-average) and
224 polydispersity index (PDI) by dynamic light scattering (DLS) using a Malvern Zetasizer Nano S
225 instrument (Malvern Instruments Ltd, UK). Moreover, the morphology of the nanocarriers was
226 evaluated by atomic force microscopy (AFM). For the preparation of AFM surfaces, a drop of the
227 nanocarrier suspension was deposited for 10 minutes on freshly cleaved mica surfaces, 0.5 x 0.5 cm
228 in size. Then, the surfaces were washed, dried, and observed with the XE-100 Atomic Force
229 Microscope (AFM, PARK System Inc., Suwon, South Korea). The employed probe was a μ Masch
230 36C with a nominal constant force of 0.6 Nm. Scanning frequency was between 0.5 and 2 Hz.
231 The instrument was set in true non-contact mode, with X–Y stage in a closed loop, while the
232 Zscanner was set in closed loop and high voltage mode. The images were analyzed by XEI
233 software (PARK Systems Inc., Suwon, South Korea).

234 Differential scanning calorimetry (DSC) studies were performed using a DSC 6000 (PerkinElmer,
235 Norwalk, USA), equipped with an intracooler (Intracooler 2, PerkinElmer, Norwalk, USA) in an inert
236 nitrogen atmosphere. CBD, PLGA and cholesterol were analyzed as powders meanwhile liposomes
237 and NPs were analyzed as liquid dispersions. A small amount (2-4 mg for the powders, 4 mg for the
238 liquid dispersions) of the samples was placed in an aluminum pan and analyzed, using an equal empty
239 pan as reference. The liquid samples were analyzed from 10 °C to 80 °C at 10 °C/min meanwhile the
240 solid samples were analyzed from 10 °C to 200 °C at 10°C/min. All runs were performed at least in
241 triplicate.

242 The loading degree (LD%) was evaluated with a direct ultracentrifugation method. Briefly, a precise
243 amount of nanocarriers was ultracentrifuged at 70000G for 1 hour and then the pellet was dissolved
244 with acetonitrile. The obtained solution was analyzed by HPLC to evaluate the content of CBD. The
245 LD% was calculated by the amount of total entrapped drug divided by the total nanocarrier weight.

246

247 **2.9 HPLC method for the analysis of CBD**

248 The content of CBD was assessed by high-performance liquid chromatography (HPLC Agilent
249 1260 Infinity II, Agilent, USA) using an isocratic mixture of 0.5 % formic acid in water and 0.5
250 % formic acid in acetonitrile (ratio 15:85) as mobile phase, with a flow rate of 1 mL/min in an

251 Agilent Poroshell 120 EC-C18, 100x4.6 mm, 2.7 μm column (Agilent, USA). The injection volume
252 was 20 μL and the detection signal was recorded at 220 nm keeping the analysis system at room
253 temperature.

254

255 **2.10 Statistics**

256 The data presented are the mean \pm standard deviation of triplicate measurements and are
257 representative of at least three independent experiments.

258

259 **3. RESULTS AND DISCUSSION**

260 **3.1. Microfluidic chips development**

261 The development of a 3D printed object starts from the computer assisted design (CAD) of the model.
262 Microfluid chips can be engineered with active or passive micromixing depending on the
263 characteristics needed. Active micromixing requests a higher complexity and the presence of an
264 external source of energy such as ultrasounds or magnetic fields. On the contrary, passive
265 micromixing does not need any external energy source because it takes advantage of the presence of
266 perturbations in the microchannels such as bas-relief, splits, 3D structures that induct a chaotic
267 advection effect. These modifications in the microfluidic channels help to increase the contact surface
268 and contact time between the species by splitting, stretching, folding, and breaking the flows
269 (Capretto et al., 2011; Hessel et al., 2005; Lee et al., 2016).

270

271 In this work, we developed two different micromixing designs with a “zigzag 3D structure” and a
272 “split and recombine circular sub-channels”. These two designs were chosen taking inspiration from
273 literature in which different microchannel shapes have been analyzed to evaluate the micromixing
274 potential. The “zigzag structure” takes advantage of the presence of bas-reliefs similar to the most
275 common herringbone structure meanwhile the “split and recombine” structure helps the mixing by
276 splitting the flow also with a change in microchannel section that create unbalanced collisions of the
277 fluid streams where the microchannels recombine together. The circular structure was selected over
278 a rhombic one since it resulted in a higher mixing performance (Ansari and Kim, 2010).


279 The FDM printing technique was selected since it presents several advantages such as a large
280 selection of relatively inexpensive materials and printers, low maintenance costs and the ease of initial
281 use. It is worth to note that even if another printing technique utilized to produce microfluidic systems
282 named stereolithography (SLA) could bring to higher accuracy and surface definition, it requires the
283 utilization of only photopolymerizing resins as manufacturing material. Most of the literature on 3D

284 printed microfluidics use their own 3D printed setup or develop their own resin, optimized for the
285 selected printer. This can result in difficulties when trying to replicate their work, limiting the
286 knowledge transfer potential (Heidt et al., 2020). In this work, using FDM we have had the possibility
287 to choose, among many different materials, PP as printing material and take the advantage of its
288 properties such as robustness, flexibility, and chemical resistance to organic solvents.

289 Figure 1A represents the 3D design of the zigzag chip (Z chip) which has two inlets that are combined
290 with a T-junction into the main channel. The main channel presents the zigzag 3D structure along all
291 its length to induce the desired chaotic mixing. The channels of this chip present a square section with
292 a section of 1 mm while the zigzag structure has a height of 500 μm . The total length of the main
293 channel is 60 mm.

294 Figure 1B represents the second microfluidic design which takes advantage of split and recombine
295 sub-channels (C chip). Also, in this case, it presents two squared inlets (1 mm side) combined with a
296 T-junction into the main channel. The subsequent circular splitting is repeated six times and kept
297 unequal to have a difference in the velocity of the fluids and therefore unbalanced collisions of the
298 fluid streams (Ansari and Kim, 2010). The major sub-channel has a section of 600 μm while the
299 minor sub-channel has a section of 400 μm both squared.

300




301

302 **Figure 1.** Computer aided design models of A) “Z” (zigzag design) microfluidic chip and B) “C” (Split and recombine
303 design) microfluidic chip.

304

305 These two models were evaluated with computational fluid dynamic (CFD) studies to assess the
306 effective micromixing potentiality. This studies also help us to confirm that the final dimensions of
307 the chips were sufficient to reach a complete mixing. Acetonitrile and ethanol were selected as the

308 organic phase against water in the two inlets of each microfluidic chip. These two solvents were
 309 selected to produce PLGA NPs and liposomes, respectively. The inlets and outlet have been assigned
 310 uniform velocity profile and zero static pressure as boundary conditions. The density of water,
 311 ethanol, and acetonitrile are 9.97×10^2 , 7.89×10^2 , and 7.86×10^2 kg/m³, respectively. FRR 1:3 and
 312 1:1 were evaluated for ACN:water (PLGA NPs) meanwhile FRR 1:3 and 1:5 were evaluated for
 313 ethanol:water (Liposomes).
 314 Figure 2 shows the distribution of the volumetric fraction of each solvent (ACN:water) with an RGB
 315 scale that represent the water fraction.




316
 317 **Figure 2.** Computational fluid dynamic simulation of Z and C chips with water and ACN. The distribution of the
 318 volumetric fraction of each solvent is represented with an RGB scale. i) and ii) show Z chip at FRR 1:1 and 1:3,
 319 respectively. iii) and iv) show C chip at FRR 1:1 and 1:3, respectively. The red color is for water and blue color is for
 320 ACN.

321
 322 These results demonstrate that the developed microfluidic chips present an effective mixing
 323 performance. In particular, the mixing was more effective at FRR 1:1 (Figure 2i, iii) for both chips
 324 reaching a complete mixing after 0.79 sec in the Z chip (Figure 2i) and after 1 sec and 3 circular sub-
 325 channels in the C chip (Figure 2iii). At FRR 1:3 (Figure 2ii, iv), the mixing performance was lower
 326 reaching a complete mixing only at the end of the microfluidic chip (1.97 sec in the Z chip and 1.6
 327 sec in the C chip). FRR 1:5 results are not shown since this parameter brought to chip occlusion due
 328 to polymer precipitation during the manufacturing of the NPs.

329 Figure 3 shows the distribution of the volumetric fraction of each solvent (ethanol:water) with an
330 RGB scale that represent the water fraction.

331




332

333 **Figure 3.** Computational fluid dynamic simulation of Z and C chips with water and ethanol. The distribution of the
334 volumetric fraction of each solvent is represented with an RGB scale. i) and ii) show Z chip at FRR 1:3 and 1:5,
335 respectively. iii) and iv) show C chip at FRR 1:3 and 1:5, respectively. The red color is for water and blue color is for
336 ethanol.

337

338 Even in this case, the mixing performance was effective at both the FRR evaluated (1:3 and 1:5)
339 confirming a potential to produce lipidic nanocarriers. The complete mixing of the two fluids was
340 reached with all the conditions studied in less than 1.9 sec (Figure 3i 1.41 sec, ii 1.87 sec, iii 1.49 sec,
341 iv 1.49 sec).

342 According to these results, the two chips were printed using polypropylene as printing material. This
343 polymer was selected because of its chemical resistance to commonly used microfluidic solvents such
344 as ACN, ethanol, acetone, and methanol (Price et al., 2020) compared to the polylactic acid (PLA)
345 commonly used to print objects with the FDM technique. During the manufacturing of the chips, the
346 effective channel dimensions were evaluated with a digital microscope (Figure 4A Z chip, Figure 4B
347 C chip) showing an accordance with the dimension of the CAD project and thus confirming the
348 optimal printing resolution. After the manufacturing of the two chips, a colored aqueous solution was
349 run through the microchannels to confirm that the fluids were free to flow through the chip (Figure
350 4C, D).



351

352 **Figure 4.** Printed channels measure of Z chip (A) and C chip (B). In the Z chip it can be observed the zigzag structure
 353 meanwhile in the C chip it is notable the asymmetric dimensions of the splitted channels. C and D show a colored aqueous
 354 solution running through the two printed chips.


355

356 **3.2 Nanocarriers manufacturing and evaluation of the influence of microfluidic parameters**

357 The two 3D-printed microfluidic chips were utilized to produce both polymeric and lipidic
 358 nanocarriers. PLGA and SPC/cholesterol were selected as model excipients as they have been already
 359 widely utilized in the production of polymeric NPs and liposomes, respectively.

360 To evaluate as the different microfluidic parameters and the chip design affect the two types of
 361 prepared nanocarriers it has been decided to perform a factor influence study applying a 2-level
 362 factorial design (Lewis et al., 1998). Once all the experimental runs provided by the DoE (table 1)
 363 were carried out and the samples characterized, it has been performed a preliminary assessment of
 364 the obtained data plotting them in an individual value plot (Figure 5). Interestingly, NPs and
 365 liposomes appear completely different, with the first showing a much wider size and polydispersity
 366 distributions with a higher median value for the size compared with the latter.

367



368


369 **Figure 5.** Individual value plot of z-average diameter and PDI. The lines above each group represent the median (central
 370 line) and the interquartile range (distance between the two outer lines).

371

372 Such results could be intrinsic to the two nanocarriers but could also be due to the FRR, which for
 373 practical reasons (Polymer precipitation and consequent chip occlusion with FRR 1:5), is the only
 374 preparation variable applied in different range for NPs and liposomes (from 1:1 to 1:3 and from 1:3
 375 to 1:5 for NPs and liposomes, respectively). To verify this hypothesis, the size and PDI of NPs and
 376 liposomes prepared at the same FRR (1:3) were compared with the t-test. The results indicate
 377 statistically significant differences and consequently the differences observed in figure 5 cannot be
 378 attributed to the different FRR range used (Supplementary figure 1). Another preliminary evaluation
 379 concerns the check of any correlation between the two responses (size and PDI) for each nanocarrier.
 380 Pearson correlation analysis has been performed and the results, once again, are specific for NPs and
 381 liposomes (Supplementary figure 2). In fact, while for liposomes no correlation was observed, for
 382 NPs size and PDI show a strong positive correlation (Pearson coefficient equal to 0.932 with a P-
 383 value lower than 0.001).

384 The size and PDI values were then analyzed through multilinear regression to assess the influence of
 385 all the experimental variables. The results of DoE analysis (Considering the type of chip, excipient
 386 concentration, TFR and FRR as variables) are summarized using Pareto plots and “main effect” and
 387 “interaction” plots (Antoy, 2014) while all the detailed results, goodness of fit statistic, residual
 388 analysis, ANOVA, and coefficient analysis are reported in the supplementary material. The fitting
 389 procedure of PDI values for liposomes resulted to be poor (R^2_{adj} lower than 0.2 and non-significant
 390 model regression), suggesting as such a value are not influenced by the four-variable studied or the
 391 mathematical model is not adequate. For this reason, the PDI of liposomes will not be more discussed
 392 subsequently. The Pareto plots reported in figure 6 show which variables have a statistically


393 significant effect on the NPs and liposomes features. Interestingly, NPs and liposomes show different
 394 behaviour concerning the role of the preparation parameters. In fact, even if the polymer and lipid
 395 concentrations represent a crucial parameter for the preparation of both nanocarriers, the size of
 396 liposomes depends also on the chip design while that of the NPs are strongly affected by the FRR and
 397 the interaction between FRR and concentration. Another noteworthy aspect concerns the fact that the
 398 TFR does not exert any effect both on NPs and liposomes, at least within the range analysed.
 399 Moreover, the Pareto plots as well as the Anova and coefficient analysis reported in the
 400 supplementary materials demonstrate as the results for the size and PDI of NPs are equivalent,
 401 confirming that these two parameters are strongly correlated.
 402



403
 404 **Figure 6.** Pareto plots for the size of the NPs (Upper left panel), for the PDI of the NPs (lower left panel), and for the size
 405 of liposomes (upper right panel). The red line represents the statistically significance limit (the t-values corresponding at
 406 a one-sided probability of 0.025 from a t distribution with the same degree of freedom of the error term) when the
 407 relevance of a variable is reported as standardized effect (t-value of the coefficient).
 408

409 The Pareto plots show the relevance of the investigated factors and their significance; however, the
 410 use of the "main effect" and "interaction" plots provides a more detailed picture of how significant
 411 factors influence responses (Antoy, 2014). The main effects and interaction plots in figure 7 refer

412 only to the factors that resulted statistically significant from the Anova and coefficient analyses. For
 413 both nanocarriers, the use of a higher polymer or lipid concentration determines a size increase. For
 414 the liposomes, a marked size increase is observed also moving from Z to C chip while in the NPs
 415 preparation an increase of the FRR produces much smaller particles. Interestingly, for each
 416 nanocarrier all the significant parameters possess an effect of comparable magnitude, determining a
 417 size variation with respect to average value of around 7% for liposomes and 24% for NPs. Finally,
 418 during the NPs preparation, a significant effect is also due to the interaction between concentration
 419 and FRR (upper right panel in figure 7). Specifically, the effect of the increase of concentration is
 420 much more relevant when a lower FRR (greater volume of the water phase) is applied. Regarding the
 421 PDI of nanoparticles, the effect of concentration and FRR (Supplementary figure 3) is quantitatively
 422 equivalent to that observed for the NPs size, a result in agreement with the strong positive correlation
 423 previously identified (Supplementary figure 2).



424
 425 **Figure 7.** Main effect plots for the size of the NPs (Upper left panel) and liposomes (lower left panel), and interaction
 426 plot for the size of the NPs (upper right panel).

427
 428 These DoE results are important to evaluate how the production parameters influence the final
 429 formulation manufactured with the 3D printed microfluidic chip. As usual, each formulation needs


430 to be optimized with specific parameters since it is impossible to obtain a universal set of values that
431 are efficient for every nanosystem.

432

433 3.3 Effect of CBD encapsulation on nanocarriers manufacturing

434 The DoE allowed understanding how the different experimental parameters affect the unloaded
435 nanocarriers' size and size distributions as a function of the chip design. The next step is to evaluate
436 the eventual effect of an encapsulated drug. As a model drug, we selected CBD, an hydrophobic
437 active molecule with a growing interest in the pharmaceutical field with different applications in a
438 large number of diseases such as dermatological problems, cancer, psychiatric disorders,
439 microbiological infections, and other (Ayati et al., 2020; Karas et al., 2020; Klein, 2005; Sheriff et
440 al., 2020). Since CBD is hydrophobic, its encapsulation into nanocarrier is useful to increase its
441 solubility in water for water-based topical formulations such as hydrogels. The CBD was
442 encapsulated in NPs and liposomes using both chips at the experimental conditions giving the highest
443 and lowest size according to the results of DoE analysis. Such experimental conditions were obtained
444 using the linear partial desirability functions that maximize and minimize the response (size) (Lewis
445 et al., 1998; Vera Candiotti et al., 2014) and are reported in the supplementary material
446 (Supplementary table 1).

447 The comparison between size and PDI (DLS size distribution plots in supplementary figure 4) for
448 unloaded and CBD-loaded nanocarriers is reported in figure 8. The presence of the CBD has a
449 marginal or null effect on the features of NPs and liposomes, which therefore still depend on the
450 experimental preparations parameters as identified with the factorial design analysis.




451

452 **Figure 8.** Comparison between the Size and PDI of unloaded and CBD-loaded NPs and liposomes. The x-axis reports
453 the experimental conditions applied where Z and C refer to the chip design and the subscript max or min to the
454 combination of parameters concentration, TFR, and FRR that maximize or minimize the size (the numerical values in
455 supplementary table 1).

456

457 Moreover, we evaluated the morphology of the four smallest manufactured loaded nanocarriers using
458 atomic force microscopy (Figure 9). The figure shows the 3D topographic images of: A) CBD loaded
459 PLGA NPs produced with Z chip; B) CBD loaded PLGA NPs produced with C chip; C) CBD loaded
460 liposomes produced with Z chip; D) CBD loaded liposomes produced with C chip. All the observed
461 nanocarriers had spherical structure with well defined regular edges and smooth surface. The average
462 size varied between 80 and 160 nm corroborating the DLS results. It is important to note that the
463 sample scanning area in AFM analysis is very small and not representative.

464



465


466 **Figure 9.** 3D images by AFM of: A) CBD loaded PLGA NPs produced with Z chip; B) CBD loaded PLGA NPs produced
467 with C chip; C) CBD loaded liposomes produced with Z chip; D) CBD loaded liposomes produced with C chip.

468

469 Thermal studies were performed to evaluate the interaction between the excipients and the active
470 (Figure 10 and supplementary figure 5). The DSC of unloaded liposomes shows the presence of two
471 endothermic transitions at around 24 and 39 °C, which could be attributed to
472 dimyristoylphosphatidylcholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC) phase
473 transitions in the bilayer (Phospholipon 90-G contains up to 94% of phosphatidylcholines). However,
474 when liposomes were loaded with CBD, the DSC traces showed the disappearance of the peak at 39
475 °C while the transition of the CBD melting was markedly enlarged. The effect of CBD on DPPC

476 transition has been previously reported by Bach et al (Bach et al., 1976) and attributed to the limited
477 solubility of cannabinoids in DPPC. Such a results suggest an interaction between CBD and
478 phosphatidylcholine, indicating that CBD is located in the bilayer, or more likely, is partially bond to
479 the bilayer.


480 For PLGA nanoparticles the DSC highlight a different behaviour. The CBD do not affect the glass
481 transition of the polymer at around 45 °C, however the CBD melting peak is very small and slightly
482 shifted at higher temperature. These results suggested as the drug is mainly encapsulated in an
483 amorphous form stabilized by the polymer.



484
485 **Figure 10.** DSC thermograms of pure CBD, liposomes and CBD loaded liposomes (CBD@liposomes) in the left panel
486 with a magnification on lipid transitions. In the right panel, DSC thermograms of CBD, PLGA NPs and CBD loaded
487 PLGA NPs (CBD@NPs) with a magnification on polymer transition.

488
489 For the loaded nanocarriers, it has been also determined the encapsulation performance of CBD. As
490 the total added amount of CBD was 3% w/w on excipient weight, it was selected the loading degree
491 (LD%) as the most suitable parameter for evaluating encapsulation, since it is independent from the
492 amount of drug added in each formulation. For each prepared nanocarrier, the LD% can range from
493 0 (no CBD encapsulated) to 3 (all the added CBD is encapsulated). The results of the LD% (Figure
494 11) highlight a different behavior between NPs and liposomes. While for the lipid carriers the LD%
495 appears almost independent of the preparation conditions, for NPs the LD% is strongly affected by
496 them and particularly it seems correlated with the size of the particles. The LD results within each
497 type of nanocarriers were further tested using one-way Anova followed by Tukey test. The results of
498 this type of analysis indicated as there were no statistically differences for the LD% for all liposomes

499 batches. Interestingly, the LD% of NPs showed a variation statistically significant only as a function
500 of the experimental conditions used (max or min) but not as a function of the chip design (Z or C).
501



502 **Figure 11.** LD% for all the CBD-loaded NPs and Liposomes. The asterisks refer to the the p-value calculated during the
503 post hoc pairwise comparison (Tukey test): * 0.05 < p < 0.01; ** 0.01 < p < 0.001; *** p < 0.001. The absence of asterisks
504 means a p > 0.05.
505

506

507 4. CONCLUSIONS

508 In this work, simple, easily manufactured 3D printed microfluidic devices have been evaluated. The
509 two developed chips resulted effective to produce model polymeric and lipidic nanocarriers. Thanks
510 to additive manufacturing technology, microfluidics became more accessible to researchers around
511 the world. Our two microfluidic chips STL files are available as supplementary material to be readily
512 printed and used. This has the potential to widen accessibility further by eliminating the design barrier
513 in addition to the fabrication barrier largely limiting access to microfluidic technology at present.
514 Every formulation that takes advantage of microfluidic manufacturing needs to be developed with
515 appropriate microfluidic parameters to reach the desired physicochemical characteristics, and the
516 most influent parameters can be evaluated by DoE as done in this work.

517 To the best of the author's knowledge, 3D printed PP based microfluidic devices have not previously
518 been realized by FDM printing for the manufacturing of nanocarriers. This is a first approach to this
519 opportunity that can lead to further designs to improve the characteristics of the microfluidic system.
520 The compromise between resolution and material choice will certainly continue to define the
521 preference for either technology.

522

523 ACKNOWLEDGMENTS

524 The authors acknowledge Fabio de Belvis for the design of the graphical abstract and Idrofoglia s.r.l.
525 and Techfem S.p.A. for their support to the chip design and computational fluid studies. Moreover,
526 we acknowledge Dr. Michele Menotta (Department of biomolecular sciences, University of Urbino
527 Carlo Bo, Urbino, Italy) for his support with AFM studies.

528

529 **Funding:** This research received no external funding.

530

531 **Conflicts of interest:** The authors declare no conflict of interest

532

533 **REFERENCES**

- 534 Ansari, M.A., Kim, K.Y., 2010. Mixing performance of unbalanced split and recombine micromixers with circular and
535 rhombic sub-channels. *Chem. Eng. J.* 162, 760–767. <https://doi.org/10.1016/j.cej.2010.05.068>
- 536 Antoy, J., 2014. A Systematic Methodology for Design of Experiments, in: *Design of Experiments for Engineers and*
537 *Scientists: Second Edition.* Elsevier Ltd, pp. 33–50. <https://doi.org/10.1016/C2012-0-03558-2>
- 538 Ayati, Z., Sarris, J., Chang, D., Emami, S.A., Rahimi, R., 2020. Herbal medicines and phytochemicals for obsessive–
539 compulsive disorder. *Phyther. Res.* <https://doi.org/10.1002/ptr.6656>
- 540 Bach, D., Raz, A., Goldman, R., 1976. The effect of hashish compounds on phospholipid phase transition. *BBA -*
541 *Biomembr.* 436, 889–894. [https://doi.org/10.1016/0005-2736\(76\)90420-X](https://doi.org/10.1016/0005-2736(76)90420-X)
- 542 Capretto, L., Cheng, W., Hill, M., Zhang, X., 2011. Micromixing within microfluidic devices. *Top. Curr. Chem.* 304, 27–
543 68. https://doi.org/10.1007/128_2011_150
- 544 Daw, R., Finkelstein, J., 2006. Lab on a chip. *Nature.* <https://doi.org/10.1038/442367a>
- 545 Desir, P., Chen, T.Y., Bracconi, M., Saha, B., Maestri, M., Vlachos, D.G., 2020. Experiments and computations of
546 microfluidic liquid-liquid flow patterns. *React. Chem. Eng.* 5, 39–50. <https://doi.org/10.1039/c9re00332k>
- 547 Gueyffier, D., Li, J., Nadim, A., Scardovelli, R., Zaleski, S., 1999. Volume-of-Fluid Interface Tracking with Smoothed
548 Surface Stress Methods for Three-Dimensional Flows. *J. Comput. Phys.* 152, 423–456.
549 <https://doi.org/10.1006/jcph.1998.6168>
- 550 Heidt, B., Rogosic, R., Bonni, S., Passariello-Jansen, J., Dimech, D., Lowdon, J.W., Arreguin-Campos, R., Steen Redeker,
551 E., Eersels, K., Diliën, H., van Grinsven, B., Cleij, T.J., 2020. The Liberalization of Microfluidics: Form 2 Benchtop
552 3D Printing as an Affordable Alternative to Established Manufacturing Methods. *Phys. status solidi* 217, 1900935.
553 <https://doi.org/10.1002/pssa.201900935>
- 554 Hessel, V., Löwe, H., Schönfeld, F., 2005. Micromixers - A review on passive and active mixing principles, in: *Chemical*
555 *Engineering Science.* pp. 2479–2501. <https://doi.org/10.1016/j.ces.2004.11.033>
- 556 Hirt, C.W., Nichols, B.D., 1981. Volume of fluid (VOF) method for the dynamics of free boundaries. *J. Comput. Phys.*
557 39, 201–225. [https://doi.org/10.1016/0021-9991\(81\)90145-5](https://doi.org/10.1016/0021-9991(81)90145-5)
- 558 Karas, J.A., Wong, L.J.M., Paulin, O.K.A., Mazeh, A.C., Hussein, M.H., Li, J., Velkov, T., 2020. The antimicrobial
559 activity of cannabinoids. *Antibiotics.* <https://doi.org/10.3390/antibiotics9070406>
- 560 Klein, T.W., 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat. Rev. Immunol.*
561 <https://doi.org/10.1038/nri1602>
- 562 Lee, C.Y., Wang, W.T., Liu, C.C., Fu, L.M., 2016. Passive mixers in microfluidic systems: A review. *Chem. Eng. J.*
563 <https://doi.org/10.1016/j.cej.2015.10.122>
- 564 Lewis, G.A., Mathieu, D., Phan-Tan-Luu, R., 1998. *Pharmaceutical Experimental Design, Pharmaceutical Experimental*
565 *Design.* CRC Press. <https://doi.org/10.1201/9780203508688>
- 566 Liu, Z., Fontana, F., Python, A., Hirvonen, J.T., Santos, H.A., 2019. Microfluidics for Production of Particles:
567 Mechanism, Methodology, and Applications. *Small.* <https://doi.org/10.1002/smll.201904673>
- 568 Martins, J.P., Torrieri, G., Santos, H.A., 2018. The importance of microfluidics for the preparation of nanoparticles as
569 advanced drug delivery systems. *Expert Opin. Drug Deliv.* <https://doi.org/10.1080/17425247.2018.1446936>
- 570 Melocchi, A., Uboldi, M., Cerea, M., Foppoli, A., Maroni, A., Moutaharrik, S., Palugan, L., Zema, L., Gazzaniga, A.,
571 2020. A Graphical Review on the Escalation of Fused Deposition Modeling (FDM) 3D Printing in the
572 Pharmaceutical Field. *J. Pharm. Sci.* <https://doi.org/10.1016/j.xphs.2020.07.011>
- 573 Mer, V.K. La, 1952. Nucleation in Phase Transitions. *Ind. Eng. Chem.* 44, 1270–1277.

574 <https://doi.org/10.1021/ie50510a027>

575 Metselaar, J.M., Lammers, T., 2020. Challenges in nanomedicine clinical translation. *Drug Deliv. Transl. Res.* 10, 721–
576 725. <https://doi.org/10.1007/s13346-020-00740-5>

577 Morgan, A.J.L., Hidalgo San Jose, L., Jamieson, W.D., Wymant, J.M., Song, B., Stephens, P., Barrow, D.A., Castell,
578 O.K., 2016. Simple and Versatile 3D Printed Microfluidics Using Fused Filament Fabrication. *PLoS One* 11,
579 e0152023. <https://doi.org/10.1371/journal.pone.0152023>

580 Pagano, S., Coniglio, M., Valenti, C., Federici, M.I., Lombardo, G., Cianetti, S., Marinucci, L., 2020. Biological effects
581 of Cannabidiol on normal human healthy cell populations: Systematic review of the literature. *Biomed.*
582 *Pharmacother.* <https://doi.org/10.1016/j.biopha.2020.110728>

583 Pranzo, D., Larizza, P., Filippini, D., Percoco, G., 2018. Extrusion-Based 3D Printing of Microfluidic Devices for
584 Chemical and Biomedical Applications: A Topical Review. *Micromachines* 9, 374.
585 <https://doi.org/10.3390/mi9080374>

586 Price, A.J.N., Capel, A.J., Lee, R.J., Pradel, P., Christie, S.D.R., 2020. An open source toolkit for 3D printed fluidics. *J.*
587 *Flow Chem.* 1–15. <https://doi.org/10.1007/s41981-020-00117-2>

588 Romanov, V., Samuel, R., Chaharlang, M., Jafek, A.R., Frost, A., Gale, B.K., 2018. FDM 3D Printing of High-Pressure,
589 Heat-Resistant, Transparent Microfluidic Devices. *Anal. Chem.* 90, 10450–10456.
590 <https://doi.org/10.1021/acs.analchem.8b02356>

591 Sheriff, T., Lin, M.J., Dubin, D., Khorasani, H., 2020. The potential role of cannabinoids in dermatology. *J. Dermatolog.*
592 *Treat.* <https://doi.org/10.1080/09546634.2019.1675854>

593 Tothill, A.M., Partridge, M., James, S.W., Tatam, R.P., 2017. Fabrication and optimisation of a fused filament 3D-printed
594 microfluidic platform. *J. Micromechanics Microengineering* 27, 035018. <https://doi.org/10.1088/1361-6439/aa5ae3>

595 Trotta, M., Peira, E., Debernardi, F., Gallarate, M., 2002. Elastic liposomes for skin delivery of dipotassium
596 glycyrrhizinate. *Int. J. Pharm.* 241, 319–327. [https://doi.org/10.1016/S0378-5173\(02\)00266-1](https://doi.org/10.1016/S0378-5173(02)00266-1)

597 Valencia, P.M., Farokhzad, O.C., Karnik, R., Langer, R., 2012. Microfluidic technologies for accelerating the clinical
598 translation of nanoparticles. *Nat. Nanotechnol.* 7, 623–629. <https://doi.org/10.1038/nnano.2012.168>

599 Vasilescu, S.A., Bazaz, S.R., Jin, D., Shimoni, O., Warkiani, M.E., 2020. 3D printing enables the rapid prototyping of
600 modular microfluidic devices for particle conjugation. *Appl. Mater. Today* 20, 100726.
601 <https://doi.org/10.1016/j.apmt.2020.100726>

602 Vera Candioti, L., De Zan, M.M., Cámara, M.S., Goicoechea, H.C., 2014. Experimental design and multiple response
603 optimization. Using the desirability function in analytical methods development. *Talanta.*
604 <https://doi.org/10.1016/j.talanta.2014.01.034>

605 Waheed, S., Cabot, J.M., Macdonald, N.P., Lewis, T., Guijt, R.M., Paull, B., Breadmore, M.C., 2016. 3D printed
606 microfluidic devices: Enablers and barriers. *Lab Chip* 16, 1993–2013. <https://doi.org/10.1039/c6lc00284f>

607 Weller, H.G., Tabor, G., Jasak, H., Fureby, C., 1998. A tensorial approach to computational continuum mechanics using
608 object-oriented techniques. *Comput. Phys.* 12, 620. <https://doi.org/10.1063/1.168744>

609 Wu, Q., Liu, J., Wang, X., Feng, L., Wu, J., Zhu, X., Wen, W., Gong, X., 2020. Organ-on-a-chip: Recent breakthroughs
610 and future prospects. *Biomed. Eng. Online.* <https://doi.org/10.1186/s12938-020-0752-0>

611 Zhao, X., Bian, F., Sun, L., Cai, L., Li, L., Zhao, Y., 2020. Microfluidic Generation of Nanomaterials for Biomedical
612 Applications. *Small* 16, 1901943. <https://doi.org/10.1002/smll.201901943>

613